Matthew R. Patterson
President and Chief Executive Officer
Mr. Patterson is the co-founder of Audentes Therapeutics and has served as president and CEO since the Company’s inception in November 2012. He has more than 20 years of experience in the research, development, and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. Previously Mr. Patterson worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed, the world’s largest health-care dedicated investment firm.
Mr. Patterson is a member of the Board of Directors of Gilda's Club of New York City, which provides social and emotional support for people living with cancer. He also currently serves as Vice Chairman of the Alliance for Regenerative Medicine (ARM). Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.
Jonathan Silverstein, J.D.
Mr. Silverstein is a General Partner and Co-Head of global venture capital at OrbiMed, the world’s largest asset management firm solely focused in healthcare with roughly $15 billion in assets under management. OrbiMed manages over a dozen different hedge, venture capital, royalty and mutual funds. OrbiMed has 110 employees throughout its five offices around the globe: New York, San Francisco, Mumbai, Shanghai and Tel Aviv. For five consecutive years, Mr. Silverstein has been named to the Forbes Midas List, a list of the world’s top 100 venture capitalists. Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University.
Louis G. Lange, M.D., Ph.D.
Dr. Lange began his career with 22 years of experience in academic medicine at Harvard and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital from 1985-1992 and was one of the first academicians in molecular cardiology. He then founded CV Therapeutics, and as Chairman, CEO and Chief Scientific Officer, led the company through an IPO in 1996, the approval of two first in class cardiovascular drugs, RANEXA® and LEXISCAN®, and the sale of the company to Gilead in 2009 for $1.4 billion dollars. Since, 1998, Dr. Lange has served as a member of the Board of Trustees at the University of Rochester and also served as Chair of the Health Affairs committee that oversaw the strategic re-invigoration of the medical center. As a member of the BIO Board of Directors from 1999 to 2009, Dr. Lange led the largest committee of member companies for two years and was picked as one of two biotech executives to attend the ceremonies at the White House for the signing of the Bioterrorism bill in 2004. Dr. Lange has been a General Partner at Asset Management since 2009, remains a senior advisor to Gilead and serves on numerous other public and private Boards in both the non-profit and for-profit arena.
Dr. Lange holds a Ph.D. degree in Biochemistry from Harvard University and an M.D. degree from Harvard Medical School. Dr. Lange has a Bachelor's degree from the University of Rochester.
Mr. Morrison was a Partner with Ernst & Young LLP from 1996 to December 2015, serving as its U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison retired in December 2015. He serves on the boards and chairs the audit committees of Global Blood Therapeutics and Corvus Pharmaceuticals. Mr. Morrison previously served on the boards of directors of the Life Sciences Foundation, the Bay Area Biosciences Association, the Biotechnology Institute and the Emerging Companies Section of the Biotechnology Innovation Organization. Mr. Morrison received a B.S. in business administration from the University of California, Berkeley.
Kush M. Parmar, M.D., Ph.D.
Kush M. Parmar, M.D., Ph.D. is a Partner at 5AM Ventures. Previously he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow at Harvard Medical School. Dr. Parmar currently serves as Director or Observer on the Boards of Achaogen, Arvinas, Audentes, Cleave, Novira and Pulmatrix. He previously served as Board Observer for Envoy (acquired by Takeda). He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals and consulted for an oncology startup. Dr. Parmar also founded a non-profit international development organization, the Cruz Blanca Initiative. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School.
Thomas J. Schuetz, M.D., Ph.D.
Dr. Schuetz, M.D., Ph.D., is the co-founder of Audentes Therapeutics and has served as a member of the board of directors since July 2013. Dr. Schuetz also provided consulting services to Audentes from July 2012 to June 2013. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed. Dr. Schuetz served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has also served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz also serves on the board of directors of Compass Therapeutics, Inc. and Glypharma, Inc. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.
Julie Anne Smith
Ms. Smith served as President and Chief Executive Officer of Raptor Pharmaceuticals, Inc. from January 2015 until the company’s recent acquisition by Horizon Pharma plc. Previously, Ms. Smith served as Raptor’s Executive Vice President and Chief Operating Officer after joining the company in September 2012 and serving as President and Chief Executive Officer Designee from July 2014 to December 2014. From 2008 to 2012, Ms. Smith served as Chief Commercial Officer of Enobia Pharma Corporation, prior to the company’s acquisition by Alexion. Additionally, Ms. Smith served in positions of increasing responsibility at Jazz Pharmaceuticals plc (2006-2008), Genzyme, Inc. (2001-2006) and Novazyme Pharmaceuticals, Inc. (2000-2001). Ms. Smith began her industry career at Bristol-Myers Squibb, first as a Product Manager and later as Director of channel strategy and design. Ms. Smith serves as an Independent Director at Exelixis, Inc. and previously as Director on the Health and Emerging Companies Sections of the Biotechnology Industry Organization (BIO) board. She received her Bachelor of Science in biological and nutritional sciences from Cornell University.
Stephen Squinto, Ph.D.
Stephen Squinto, Ph.D., has over 25 years of experience in the biotechnology industry, as both a scientist and senior executive. He is currently a Venture Partner with OrbiMed. Dr. Squinto was a co-founder of Alexion Pharmaceuticals Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion's Global Head of Research and Development. Alexion is dedicated to developing therapies for certain rare and ultra-rare diseases. From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work.
Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.
Thomas Woiwode, Ph.D.
Tom has been with Versant Ventures since 2002, serving as a Venture Partner since 2008 while taking on operating roles in a number of portfolio companies. Most recently, Tom served as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. Tom led the process that culminated in the sale of Okairos to GlaxoSmithKline for $325M. Prior to his role with Okairos, Tom co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (private), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb for up to $475M). Prior to his role as a Venture Partner, Tom was a Principal at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. Tom was a research scientist at XenoPort before joining Versant. Tom earned his PhD in Organic Chemistry as an NSF Fellow at Stanford University and graduated summa cum laude with a BA in English and received the Departmental Citation for his B.S. in Chemistry from UC Berkeley.
Tom lives with his family in Basel, Switzerland, where he has helped build Versant’s biotech practice in Europe.